In a joint statement Danish drugmaker Novo Nordisk and U.S. drug developer Prothena Corp said, the former will acquire the latter’s experimental heart therapy PRX004, in a deal that could be worth up to $1.23 billion. Novo’s acquisition is in… Read More ›
On Monday, Swiss pharmaceutical giant Roche stated, it has hired a professor from the Massachusetts Institute of Technology (MIT) as its new head of its U.S. research arm which was responsible for some of it’s best-selling medicines in the last… Read More ›
Shareholders are scheduled to vote on Novartis’s planned spin-off of its Alcon eye care unit. On Thursday, at the annual general meeting of Swiss drugmaker Novartis, shareholders came in heavily at the drugmaker for the hike in drug prices. Novartis… Read More ›
The strategic development places the Ian Read as its chairman and opens up the CEO post which could be filled at a later date. Under Read’s steady stewardship, Pfizer Inc’s stock has gone up by 160% since December 2010. Pfizer… Read More ›
The company has added three new directors to its board, thus extending it to 14 directors. NY-based activist investor, JANA partners has boosted its stake in the company, although sources say it is less than 1%. In a move that… Read More ›
manageria.biz 